Katja Pekrun

Apr 28, 2023 | nature.com | Katja Pekrun |Shinnosuke Tsuji |L. T. Hung |Howard Chang

AbstractRecombinant adeno-associated viral vectors (rAAVs) are among the most commonly used vehicles for in vivo based gene therapies. However, it is hard to predict which AAV capsid will provide the most robust expression in human subjects due to the observed discordance in vector-mediated transduction between species.